New Study by Yale University Raises Concerns About E-Cigarettes

News by 2FIRSTS.ai
Aug.13.2024
New Study by Yale University Raises Concerns About E-Cigarettes
Yale study reveals some e-cigarettes may contain potent nicotine-like chemicals, raising health concerns beyond FDA regulation.

According to a report by Newsweek on August 12, a previous study by Yale University found that some e-cigarettes may contain chemical compounds similar to nicotine that could have unknown effects on health.


These nicotine alternatives interact with receptors in the brain, without being subject to FDA restrictions and regulations. As a result, these products are able to be marketed with flavors that appeal to young people and avoid tobacco taxes.


An FDA spokesperson stated that these new chemicals may be more potent than nicotine and could potentially affect the brain development, learning abilities, and memory of adolescents.


FDA Public Affairs Specialist Jim McKinney told Newsweek that...


The FDA is addressing this issue from the perspective of the entire agency and will continue to utilize all resources within its authority to protect the public, especially American adolescents, from potentially harmful addictive products.


McKinney points out that, although more research is needed, some emerging data suggests that these nicotine analogs may be more potent than nicotine itself, which is already highly addictive, altering adolescent brain development and producing long-term effects.


According to research, nicotine analogs are chemical substances that are structurally very similar to nicotine and therefore target the same receptors in the brain. Examples include 6-methyl nicotine and nicotineamide. A study in rodents suggests that 6-methyl nicotine may be more toxic than nicotine. Furthermore, because these compounds are not subject to the same strict regulations as traditional nicotine, the ingredients listed on labels may not always match the actual ingredients in the products.


Dr. Hanno Erythropel, a scientist at the Yale School of Medicine, stated in a press release,


In conclusion, the company is actually trying to evade regulation by introducing new products containing nicotine analogues with unknown health and addiction risks.


In a study published in the journal "JAMA Network," the researcher and their colleagues analyzed two e-cigarette and e-liquid products on the market. The first product, Spree Bar, claimed to contain 5% of 6-methyl nicotine (50 milligrams/gram), while the second product, Nic-Safe, was tested at four concentrations—0, 12, 24, and 36 milligrams/milliliter.


The research results show that both products do not contain the ingredients as specified on their labels. Spree Bar actually contains 90% less 6-methyl nicotine than advertised, while Nic-Safe contains a low concentration of 6-methyl nicotine without it being clearly marked on the label (excluding tested nicotine-free products).


FDA spokesperson Mackinney said that


In general, the FDA does not comment on specific studies, but instead uses them as part of the evidence to further understand specific issues and help achieve its mission of protecting public health. Regarding nicotine mimetics, the FDA is aware that some companies are reported to be producing products that may contain compounds with chemical structures or properties different from nicotine.


We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

GAO Audit Finds Nearly 132,000 FDA Tobacco Applications Waiting an Average 1,266 Days as Nicotine Pouch Pilot Practices Move Into Vape PMTA Reviews
GAO Audit Finds Nearly 132,000 FDA Tobacco Applications Waiting an Average 1,266 Days as Nicotine Pouch Pilot Practices Move Into Vape PMTA Reviews
A U.S. Government Accountability Office audit found that 131,915 tobacco product applications submitted to the FDA since 2018 remained without a final review as of December 31, 2025, with pending applications waiting an average of 1,266 days. GAO also found FDA lacks the data needed to systematically determine whether scientific reviews meet applicable timelines. HHS agreed to upgrade the agency's tracking systems. At the same time, FDA has begun applying lessons from its nicotine pouch PMTA pilot to e-cigarette reviews, while changes to enforcement policy and electronic submissions are making the specific stage of a PMTA increasingly relevant to market access.
FDA
Oct.03
Reynolds Puts Nearly 183,000 U.S. Contracted Outlets Under Age-Verification Rules, Covering 94% of Volume — Can It Shift an Unauthorized Vape Market?
Reynolds Puts Nearly 183,000 U.S. Contracted Outlets Under Age-Verification Rules, Covering 94% of Volume — Can It Shift an Unauthorized Vape Market?
Reynolds American says nearly 183,000 U.S. retail outlets are under contract, with its Retail Marketing Plan Contract covering about 94% of company volume and requiring point-of-sale age verification. The company combines those contracts with We Card, TruAge, NACS-linked infrastructure and POS integration, while enhanced Vuse Pro retail rules add ID scanning, purchase limits and stronger underage-sales accountability. The initial Vuse Pro rollout targets about 50,000 stores. The system is taking shape as unauthorized vapor products remain dominant in parts of the U.S. market: a 2026 study estimated they accounted for 69.4% of tracked brick-and-mortar e-cigarette dollar sales in December 2025.
Special Report
Oct.15
Product | Four CrossBar 20K 13mL High-Puff Vapes Listed on Pennsylvania's ENDS Directory, Rated for Up to 20,000 Puffs
Product | Four CrossBar 20K 13mL High-Puff Vapes Listed on Pennsylvania's ENDS Directory, Rated for Up to 20,000 Puffs
Four CrossBar 20K disposable e-cigarettes appeared on Pennsylvania's 163-entry ENDS directory ahead of enforcement beginning October 19, 2026. The devices feature 13mL e-liquid reservoirs, 50mg/mL nicotine, 2,000mAh batteries and 0.9Ω mesh coils, with advertised puff counts of up to 20,000. CrossBar was the only modern high-puff disposable series among the directory's 15 disposable entries. Its packaging emphasizes New York design and Japanese-origin flavoring, while historical CrossBar records identify a registered U.S. tobacco manufacturing-related establishment. The link between the newer 13mL devices and earlier 1.3mL PMTA filings remains unconfirmed.
product
Oct.26
Wall Street Journal: U.S. FDA Plans Faster Vape and Nicotine Pouch Reviews, Revisit of 2021 PMTA Rule
Wall Street Journal: U.S. FDA Plans Faster Vape and Nicotine Pouch Reviews, Revisit of 2021 PMTA Rule
The Trump administration is preparing changes intended to accelerate FDA market authorization reviews for e-cigarettes and nicotine pouches, according to The Wall Street Journal. The FDA is expected to revisit its 2021 PMTA rule and may simplify some scientific study requirements and shorten review times. The agency has not formally announced the changes. Over the past year, the FDA has already accelerated nicotine-pouch reviews, expanded ENDS authorizations and upgraded its CTP Portal NextGen application system. As of August 2026, 43 nicotine pouch products and 48 e-cigarette products had received FDA marketing authorization.
Sep.24
Japan's Heated Tobacco Use Rises From 0.1% to 14.9% Over a Decade as Growth Extends Beyond Cigarette Switching
Japan's Heated Tobacco Use Rises From 0.1% to 14.9% Over a Decade as Growth Extends Beyond Cigarette Switching
A decade-long study published in The Lancet Regional Health – Western Pacific found that heated tobacco product use in Japan increased from 0.1% in 2015 to 14.9% in 2025, although growth slowed after 2018. Switching from conventional cigarettes remained an important source of HTP uptake, while the contribution from previously non-current users increased. Approximately 56% of HTP users also smoked conventional cigarettes in 2025. Separate industry data show that Japan's heated tobacco sales reached 73.4 billion units in fiscal 2025, approaching conventional cigarette sales of 78.2 billion units.
SCIENCE
Nov.10
Iowa's First Vape Directory Lists JUUL and Vuse Pod Systems Alongside Loon and Crossbar Disposables, With 20,000-Puff Products Listed Across States
Iowa's First Vape Directory Lists JUUL and Vuse Pod Systems Alongside Loon and Crossbar Disposables, With 20,000-Puff Products Listed Across States
Iowa published its first vapor products directory on November 16, 2026, listing 361 product entries, including 175 covering prefilled pods, devices, kits and disposable e-cigarettes. Established tobacco-company brands such as JUUL and Vuse appear alongside independent disposable brands including Loon, Crossbar and Z Stick. The products range from traditional small-capacity disposables to Crossbar's 13mL, 20,000-puff devices. Of the 361 records, 288 are marked FDA Pending. Both Crossbar entries were dated November 16 and carry UPCs also found in other state directories. By contrast, a matching Z Stick product lost its active Louisiana listing after its certification was not renewed.
Regulations
Nov.17